Intrust Bank NA boosted its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 11.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,051 shares of the specialty pharmaceutical company’s stock after buying an additional 535 shares during the period. Intrust Bank NA’s holdings in ANI Pharmaceuticals were worth $236,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BNP Paribas Arbitrage SA boosted its position in ANI Pharmaceuticals by 44.6% in the second quarter. BNP Paribas Arbitrage SA now owns 2,152 shares of the specialty pharmaceutical company’s stock valued at $101,000 after buying an additional 664 shares in the last quarter. Envestnet Asset Management Inc. raised its position in shares of ANI Pharmaceuticals by 82.3% in the first quarter. Envestnet Asset Management Inc. now owns 3,493 shares of the specialty pharmaceutical company’s stock valued at $172,000 after buying an additional 1,577 shares during the last quarter. Municipal Employees Retirement System of Michigan raised its position in shares of ANI Pharmaceuticals by 132.0% in the second quarter. Municipal Employees Retirement System of Michigan now owns 4,200 shares of the specialty pharmaceutical company’s stock valued at $197,000 after buying an additional 2,390 shares during the last quarter. Oppenheimer Asset Management Inc. bought a new position in shares of ANI Pharmaceuticals during the first quarter valued at $204,000. Finally, Thrivent Financial For Lutherans raised its position in shares of ANI Pharmaceuticals by 5.1% in the first quarter. Thrivent Financial For Lutherans now owns 4,520 shares of the specialty pharmaceutical company’s stock valued at $224,000 after buying an additional 220 shares during the last quarter. 55.86% of the stock is owned by hedge funds and other institutional investors.

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) opened at 45.72 on Thursday. The stock has a 50 day moving average of $46.42 and a 200 day moving average of $49.30. The firm has a market capitalization of $532.09 million, a price-to-earnings ratio of 100.04 and a beta of 3.08. ANI Pharmaceuticals, Inc. has a 52-week low of $42.23 and a 52-week high of $69.85.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.19. The business had revenue of $44.80 million for the quarter, compared to the consensus estimate of $43.20 million. ANI Pharmaceuticals had a net margin of 3.35% and a return on equity of 22.70%. ANI Pharmaceuticals’s revenue for the quarter was up 43.0% on a year-over-year basis. During the same period last year, the company posted $1.11 EPS. On average, analysts predict that ANI Pharmaceuticals, Inc. will post $3.84 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/31/intrust-bank-na-has-236000-stake-in-ani-pharmaceuticals-inc-anip.html.

Several brokerages have weighed in on ANIP. Roth Capital set a $56.00 target price on shares of ANI Pharmaceuticals and gave the stock a “hold” rating in a research report on Saturday, May 6th. BidaskClub lowered shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Zacks Investment Research upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 3rd. Canaccord Genuity restated a “buy” rating and set a $60.00 target price on shares of ANI Pharmaceuticals in a research report on Wednesday, August 9th. Finally, ValuEngine lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $65.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP).

Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Stock Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.